(Q37427251)

20 August 2017

1 reference

title

Improving microvascular outcomes in patients with diabetes through management of hypertension (English)

1 reference

20 August 2017

main subject

arterial hypertension

0 references

microvessel

0 references

author name string

Janet B McGill

series ordinal

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 March 2009

1 reference

20 August 2017

published in

Postgraduate Medicine

1 reference

20 August 2017

volume

121

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

89-101

1 reference

Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Increasing incidence of type 2 diabetes in children and adolescents: treatment considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Increased incidence of non-insulin-dependent diabetes mellitus among adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Vascular risk factors and diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Concomitance of diabetic retinopathy and proteinuria accelerates the rate of decline of kidney function in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Nonalbuminuric renal insufficiency in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Histopathology of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

How the diabetic eye loses vision.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

21 January 2018

Retinopathy in diabetes

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Do angiographic data support a detailed classification of hypertensive fundus changes?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Long-term follow-up after tight control of blood pressure in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Impact of diabetes and hypertension on the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Standards of medical care in diabetes--2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

ASH position paper: treatment of hypertension in patients with diabetes-an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

RAS inhibition in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Is it time to move to multidrug combinations?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Combination drug treatment of hypertension: have we come full circle?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Card

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Hypertension and kidney disease: a deadly connection

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Is serum cystatin-C a reliable marker for metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

Hypertension Increases Retinal Inflammation in Experimental Diabetes: A Possible Mechanism for Aggravation of Diabetic Retinopathy by Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1980

21 January 2018

Identifiers

DOI

10.3810/PGM.2009.03.1980

1 reference

20 August 2017

1 reference